Healthy
Conditions
Keywords
Positron Emission Tomography study in healthy volunteers for ligand qualification and receptor occupancy determination.
Brief summary
The primary purpose of this study is to assess central receptor occupancy of PF 03654746 at the H3 receptor after a single oral dose of PF 03654746.
Detailed description
Additional Study Purpose Details: To validate PET ligand which will be used to determine receptor occupancy and to determine receptor occupancy of PF-0367456
Interventions
OTHERPositron Emission tomography
Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
DRUGPET Scan with PF-03654746
If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
Sponsors
Yale University
Pfizer
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
MALE
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy male subjects between the ages of 18 and 55 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG and clinical laboratory tests). * Body Mass Index (BMI) of approximately 18 to 30 kg/m2; and a total body weight \>50 kg (110 lbs). A BMI at the lower limit of 17.5 kg/m2 may be rounded up to 18.0 kg/m2; a BMI upper limit of 30.5 kg/m2 may be rounded down to 30.0 kg/m2 and will be acceptable for inclusion. * An informed consent document signed and dated by the subject or a legally acceptable representative. * Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion criteria
* Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease or clinical findings at Screening. * History of febrile illness within 5 days prior to the first dose. * Any condition possibly affecting drug absorption (eg, gastrectomy). * A positive urine drug screen at Screening or Day 0. * History of regular alcohol consumption exceeding 14 drinks/week for men (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening. * Positive cotinine screen at Screening or Day 0. * Treatment with an investigational drug within 30 days or 5 half-lives preceding the first dose of study medication (excluding \[C-11\]PF-04621053). * 12-lead ECG demonstrating QTc \>450 msec at Screening. If QTc exceeds 450 msec, the ECG should be repeated two more times and the average of the three QTc values should be used to determine the subject's eligibility. * Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. Herbal supplements must be discontinued 28 days prior to the first dose of study medication. * Chronic (every day) use of a histamine (H1, H2) inhibitor(s) within 3 months before screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall H3 Receptor Occupancy of PF 03654746. | 48 hours |
Secondary
| Measure | Time frame |
|---|---|
| Binding potential (BP) of [C-11]PF 04621053. | 48 hours |
| Relationship between serum PF 03654746 concentration and H3 RO (IC50). | 48 hours |
| H3 RO of PF 03654746 at regions of interest in man | 48 hours |
Countries
United States
Outcome results
None listed